PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Julia:ReplicateBE – release 0.2.0

Опубликовано 26 октября, 201926 октября, 2019 frozencat

doiGitHub

Вот и подоспел релиз 0.2.0 для оценки параметров смешанной модели репликативного дизайна биоэквивалентности по методу С (EMA) – FDA model.

 

Рубрики: IT, Julia, Mixed Model, Биоэквивалентность

Навигация по записям

Предыдущая запись: ClinicalTrialUtilities: обзор
Следующая запись: Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4

Свежие записи

  • Оценка данных вариации литературных источников для определения объема выборки клинических исследований биоэквивалентности
  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4

Галерея

20170729 215051
20180814 165255
20180202 170523
20170803 172540
DJI 0041
20170804 134138
  • CDER Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality (CDER Quality Standards Program)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-03 By FDA
  • Medication Health Fraud
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-03 By FDA
  • FDA and Kratom
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-03 By FDA
  • Hiding in Plain Sight: 7-OH Products
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-03 By FDA
  • FDA warns about heavy metal poisoning associated with certain unapproved ayurvedic drug products
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-03 By FDA
  • Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-03 By FDA
  • Fraudulent Products
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-03 By FDA
  • Public Meeting on the Reauthorization of the Biosimilar User Fee Act (BsUFA) - 12/03/2025
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-12-02 By FDA
  • Recently Issued Guidance Documents
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-02 By FDA
  • Labeling and Promotion Guidances
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-12-02 By FDA
  • Bioresearch Monitoring Information System (BMIS)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-12-02 By FDA
  • FDA Grand Rounds – Advancing Real-World Evidence in FDA Regulatory Decision Making - 12/11/2025
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-12-02 By FDA
  • Human medicines European public assessment report (EPAR): Kaletra, lopinavir,ritonavir, Date of authorisation: 19/03/2001, Revision: 65, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-12-02
  • Human medicines European public assessment report (EPAR): Pregabalin Sandoz, pregabalin, Date of authorisation: 19/06/2015, Revision: 23, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-12-02
  • Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-12-02
Older posts
Тема: Scaffold от Danny Cooper.